Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013852:Thiotepa / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014747:Vinblastine; D008130:Lomustine; D013852:Thiotepa